PE122599A1 - Nuevas formas polimorficas cristalinas de cipamfilina - Google Patents

Nuevas formas polimorficas cristalinas de cipamfilina

Info

Publication number
PE122599A1
PE122599A1 PE1998001002A PE00100298A PE122599A1 PE 122599 A1 PE122599 A1 PE 122599A1 PE 1998001002 A PE1998001002 A PE 1998001002A PE 00100298 A PE00100298 A PE 00100298A PE 122599 A1 PE122599 A1 PE 122599A1
Authority
PE
Peru
Prior art keywords
cypamfiline
new
polymorphic forms
crystalline polymorphic
refers
Prior art date
Application number
PE1998001002A
Other languages
English (en)
Inventor
Drake Eggleston
Ian Robert Lynch
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE122599A1 publication Critical patent/PE122599A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A POLIMORFOS CRISTALINOS (FORMA I, II Y IV) DE 1,3-DICICLOPROPILMETIL-8-AMINOXANTINA (CIPAMFILINA), QUE SE CARACTERIZAN POR SUS PROPIEDADES FISICAS COMO SU PATRON DE DIFRACCION DE RAYOS X, SU ESPECTRO DE ABSORCION INFRARROJO, POR SU ANALISIS CRISTALOGRAFICO POR RAYOS X, A TRAVES DE MONOCRISTALES, SU ESPECTROSCOPIA RAMAN; TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE a)DISOLVER 1,3-DICICLOPROPILMETIL-8-AMINOXANTINA EN 1-PROPANOL MEZCLADO CON AGUA; b)ENFRIAR LA DISOLUCION, A 25°C PARA QUE CRISTALICE LA FORMA I POLIMORFICA. LA CIPAMFILINA ES UN INHIBIDOR DE FOSFODIESTERASA (PDE4) Y DEL FACTOR DE NECROSIS TUMORAL (TNF)
PE1998001002A 1997-10-23 1998-10-23 Nuevas formas polimorficas cristalinas de cipamfilina PE122599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6323897P 1997-10-23 1997-10-23

Publications (1)

Publication Number Publication Date
PE122599A1 true PE122599A1 (es) 2000-02-12

Family

ID=22047900

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001002A PE122599A1 (es) 1997-10-23 1998-10-23 Nuevas formas polimorficas cristalinas de cipamfilina

Country Status (28)

Country Link
US (2) US6583283B1 (es)
EP (1) EP1025103A4 (es)
JP (1) JP2001520228A (es)
KR (1) KR20010031246A (es)
CN (1) CN1280579A (es)
AP (1) AP2000001793A0 (es)
AR (1) AR015190A1 (es)
AU (1) AU751561B2 (es)
BG (1) BG104368A (es)
BR (1) BR9814099A (es)
CA (1) CA2306980A1 (es)
CO (1) CO4990930A1 (es)
DZ (1) DZ2629A1 (es)
EA (1) EA003445B1 (es)
HU (1) HUP0100019A3 (es)
ID (1) ID23885A (es)
IL (1) IL135711A0 (es)
MA (1) MA24682A1 (es)
NO (1) NO20002012D0 (es)
NZ (1) NZ504051A (es)
PE (1) PE122599A1 (es)
PL (1) PL340257A1 (es)
SA (1) SA99191117A (es)
SK (1) SK5642000A3 (es)
TR (1) TR200001109T2 (es)
UY (2) UY25220A1 (es)
WO (1) WO1999020625A1 (es)
ZA (1) ZA989622B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156460A0 (en) 2001-01-31 2004-01-04 Pfizer Prod Inc Ether derivatives useful as inhibitors of pde4 isozymes
EP1355884A1 (en) 2001-01-31 2003-10-29 Pfizer Products Inc. Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
WO2002060898A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
JP2005529933A (ja) * 2002-05-31 2005-10-06 シェーリング　コーポレイション キサンチンホスホジエステラーゼｖインヒビター多形体
WO2006078287A2 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
AU2005279795A1 (en) 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl PDE4B inhibitors
EP2082741A1 (en) * 2005-09-20 2009-07-29 Scinopharm Singapore Pte, Ltd. Novel crystal form of irinotecan hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
HUP0100019A3 (en) 2003-01-28
AU1274499A (en) 1999-05-10
ZA989622B (en) 1999-04-23
UY25380A1 (es) 1999-11-17
SA99191117A (ar) 2005-12-03
KR20010031246A (ko) 2001-04-16
BR9814099A (pt) 2000-10-10
BG104368A (en) 2001-02-28
IL135711A0 (en) 2001-05-20
AU751561B2 (en) 2002-08-22
SK5642000A3 (en) 2000-09-12
NO20002012L (no) 2000-04-17
CO4990930A1 (es) 2000-12-26
ID23885A (id) 2000-05-25
NZ504051A (en) 2003-02-28
NO20002012D0 (no) 2000-04-17
EA200000448A1 (ru) 2000-10-30
CA2306980A1 (en) 1999-04-29
DZ2629A1 (fr) 2003-03-08
EP1025103A1 (en) 2000-08-09
EA003445B1 (ru) 2003-06-26
AP2000001793A0 (en) 2000-06-30
JP2001520228A (ja) 2001-10-30
TR200001109T2 (tr) 2000-09-21
US6583283B1 (en) 2003-06-24
WO1999020625A1 (en) 1999-04-29
CN1280579A (zh) 2001-01-17
UY25220A1 (es) 2001-08-27
MA24682A1 (fr) 1999-07-01
US20020173648A1 (en) 2002-11-21
HUP0100019A2 (hu) 2002-01-28
PL340257A1 (en) 2001-01-29
AR015190A1 (es) 2001-04-18
EP1025103A4 (en) 2001-11-14

Similar Documents

Publication Publication Date Title
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
DE3576331D1 (de) Tetralin-derivate, ihre herstellung und verwendung.
PE122599A1 (es) Nuevas formas polimorficas cristalinas de cipamfilina
UY27906A1 (es) Inhibidores de quinasas
CR9365A (es) Compuestos y metodos para la inhibicion de la protein-cinasa raf
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
ES2133800T3 (es) Pirimido(5,4-d)pirimidinas, medicamentos que contienen estos compuestos, su uso y su procedimiento de preparacion.
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
ES2162942T3 (es) Nuevos derivados de acidos carboxilicos, su obtencion y empleo.
BRPI0415760A (pt) derivados de benzimidazolila
CL2009000648A1 (es) Propeptido bmp-11 modificado en el residuo 98 de una secuencia bmp-11 humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; metodo para preparar el propeptido, celula recombinante; uso del propeptido para tratar desordenes musculares, neuromusculares, metabolicos, y degenerativos de los huesos (divisional sol.224-02).
AR064035A1 (es) Polimorfos de la sal succinato de 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo y sus metodos de uso
BR0111358A (pt) Compostos de tioacetamida e seu uso
ES525653A0 (es) Procedimiento para preparar nuevos diazabiciclo-(3.3.1)-nonanos
MX9307974A (es) Nuevos derivados de acido hidroxiiminoalquilindolcarboxilico, su obtencion y uso.
BR0316296A (pt) Compostos lapacone e seus métodos de uso
BR0115080A (pt) Derivados de acila e sulfonila de 2-(trans-1,4-diaminocicloexil)-purinas 6,9-dissubstituìdas e o uso destes como agentes antiproliferativos
HRP20090513T1 (en) S-mirtazapine for the treatment of hot flush
ECSP077306A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparación y su uso como antiinflamatorios
Freeman et al. Ultraviolet wavelength factors in solar radiation and skin cancer.
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
HN1999000196A (es) Derivados de indol
ES2193248T3 (es) Antraquinonas mono- y disulfosustituidas y su uso para el tratamiento de desordenes de la matriz osea.
CY1105765T1 (el) Πυρανο πιπepιδιο και θειοπυρανο ενωσεις και μεθοδοι χρησης
ES2160768T3 (es) Procedimiento de obtencion de la forma polimorfica i de d4t.

Legal Events

Date Code Title Description
FD Application declared void or lapsed